GSK's $10.6B Nuvalent Buy; Lilly & Merck Post Trial Results

GSK Plc agreed to acquire Nuvalent Inc. for $10.6 billion, securing the U.S. biotech's pipeline of treatments for lung cancer as part of the British pharmaceutical company's effort to rebuild its oncology franchise. The transaction represents one of the largest recent acquisitions in the oncology space and underscores Big Pharma's appetite for clinical-stage cancer assets.

Johnson & Johnson ($JNJ) paid $1 billion to access a platform delivering protein-degrading drugs directly into KRAS-driven tumor cells, targeting an historically undruggable cancer mechanism. Additionally, Eli Lilly and Company ($LLY) entered into a collaboration and out-licensing agreement with Sweden's AlzeCure Pharma for an Alzheimer's disease project, though financial terms were not disclosed. The deals reflect sustained M&A momentum across oncology and neuroscience therapeutic areas.

Gilead Sciences ($GILD) and Merck ($MRK) announced that the primary efficacy endpoint at Week 48 was met in both Phase 3 ISLEND-1 and ISLEND-2 trials evaluating the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg. The companies plan global regulatory filings based on the data, which showed a comparable safety profile to standard daily treatments. At the same time, $MRK and $GILD discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy in combination with Merck's KEYTRUDA compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer, after the combination failed to show a statistically significant improvement.

Eli Lilly ($LLY) reported new ATTAIN trial data showing its weight-loss pill retatrutide delivered up to 30.4 lbs lost across perimenopause and post-menopause groups, strengthening the company's lead in obesity treatments. Moderna ($MRNA) and the University of Oxford received UK authorization to begin a Phase 1/2 study of an investigational mRNA cancer vaccine for people with Lynch syndrome, an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%. Sciwind reported 12.8% weight loss with ecnoglutide in a China study of 163 patients, outperforming semaglutide in the trial.

The UK's National Institute for Health and Care Excellence (NICE) has preliminarily recommended D-VRd (daratumumab, lenalidomide, bortezomib, and dexamethasone) for NHS use as a first-line treatment for transplant-ineligible multiple myeloma, following an earlier refusal. The extended approval for Johnson & Johnson's ($JNJ) Darzalex represents a significant reimbursement win in a key European market. $MRNA and the University of Oxford received UK authorization to begin the INTERCEPT-Lynch trial, part of a scientific collaboration to advance a novel mRNA cancer vaccine. The Hashgraph Group and Merck ($MRK) introduced an EU Digital Product Passport on Hedera for regulated supply chains, designed to support compliance requirements for the global supply chain industry and meet the EU's incoming product transparency regulations.

Goldman Sachs lowered its price recommendation on Amgen Inc. ($AMGN) to $389 from $425 while reiterating a Buy rating, adjusting its model after the company disclosed updated information. Morgan Stanley raised its price recommendation on UnitedHealth Group Incorporated ($UNH) to $453 from $395, maintaining an Overweight rating as managed care stocks have been grinding higher. HSBC downgraded Thermo Fisher Scientific Inc. ($TMO) to Hold from Buy and lowered its price target to $540 from $670, citing concerns that the company's goal of returning to 7% growth may face challenges. Abbott Laboratories ($ABT) has risen 3.7% over the past week and 8.0% over the past month, yet remains down 26.7% year to date and down 30.3% over the last year.

Convatec, a medical products and technologies company, and The Eli Lilly and Company Foundation committed approximately $5 million to Partners In Health, an international nonprofit global health organization, to help accelerate the integration of non-communicable disease (NCD) and chronic conditions care. The collaboration aims to improve care delivery for NCDs in underserved populations globally. The commitment reflects pharmaceutical industry efforts to address chronic disease management beyond drug development and commercial operations.